Showing results (41-50 of 159) with videos related to

Sort By:
Pageof 16
Cancer Treatment Reviews|September 10, 2014
Therapeutic options in relapsed or refractory peripheral T-cell lymphomaBertrand Coiffier, Massimo Federico, Dolores Caballero, et al.
Nuclear Medicine Communications|July 25, 2013
Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatmentEva González-Barca, Miguel Canales, Montse Cortés, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow TransplantationCharalampia Kyriakou, Carmen Canals, Anthony Goldstone, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 21, 2008
Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxisJose A Pérez-Simón, Rodrigo Martino, Dolores Caballero, et al.
Transfusion|October 26, 2011
Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantationFermin M Sánchez-Guijo, Olga López-Villar, Lucía López-Anglada, et al.
Haematologica|February 29, 2012
Evaluation of prognostic factors among patients with chronic graft-versus-host diseaseJose A Pérez-Simón, Gabriel Afram, Rodrigo Martino, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 23, 2008
Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapyJosé A Pérez-Simón, Cristina Encinas, Fernando Silva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-)Dolores Caballero, Jose A García-Marco, Rodrigo Martino, et al.
Bone Marrow Transplantation|January 3, 2024
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II TrialMónica Cabrero, Lucia López-Corral, Isidro Jarque, et al.
Histopathology|March 29, 2011
Flow cytometry immunophenotyping of fine-needle aspiration specimens: utility in the diagnosis and classification of non-Hodgkin lymphomasSusana Barrena, Julia Almeida, María Del Carmen García-Macias, et al.
Pageof 16